10/28/2026
Reality star Ronnie Ortiz-Magro credits ibogaine for sobriety
The Jersey Shore star reports four months of sobriety after treatment in Mexico.
Topic archive
fda
28 stories
10/28/2026
Sister's ibogaine treatment ends in tragedy
A personal account highlights the risks of unregulated ibogaine use.
10/20/2026
Psychedelics fast-tracked by FDA under Trump order
Executive order allocates $50 million for psychedelic drug development, including ibogaine.
10/19/2026
FDA seeks input on ibogaine trial design, advances psychedelic framework
FDA's request for ibogaine trial input marks a step in psychedelic drug regulation.
10/14/2026
Ibogaine's potential in addiction treatment faces cardiac risks
New review highlights ibogaine's promise and dangers in addiction therapy.
10/9/2026
FDA faces internal dissent over HHS peptide legalization
HHS plans to allow unapproved peptides, sparking FDA staff concerns.
10/8/2026
Texas ibogaine trials face funding gap as federal support looms
Federal funds may replace private investment in Texas ibogaine research
10/7/2026
FDA proposes strict ibogaine trial guidelines
Public input sought on inpatient care and heart monitoring
10/6/2026
FDA seeks public input on ibogaine trial design
Request focuses on safety, dosing, and oversight for early-phase trials.
10/5/2026
FDA considers framework for ibogaine trials
The FDA is evaluating guidelines for ibogaine clinical trials.
10/5/2026
Psyence BioMed partners with Benuvia for ibogaine production
Agreement aims to produce pharmaceutical-grade ibogaine in Texas facility.
10/5/2026
FDA seeks public input on ibogaine research
Agency requests feedback on clinical trial design for ibogaine drug products.
9/23/2026
Ibogaine under scrutiny after Presley Gerber's death
No link established between ibogaine and Gerber's death, but heart risks persist.
9/23/2026
Dr. Drew Pinsky warns on ibogaine in addiction treatment
Presley Gerber's death raises concerns over alternative therapies in rehab.
9/22/2026
NIH funds ibogaine study for opioid addiction with heart safety focus
Brigham and Women's Hospital receives $2.3 million to assess ibogaine's safety for opioid use disorder.
9/22/2026
Ibogaine treatment and the case of Presley Gerber
Presley Gerber's use of ibogaine highlights its controversial role in addiction treatment.
9/17/2026
Ibogaine research advances in U.S. and Israel for PTSD
Psychedelic therapies gain momentum as potential treatments for combat-related trauma.
9/16/2026
FDA hearing highlights psychedelic drug trial safety
Public feedback sought on psychedelic drugs' therapeutic potential and safety measures.
9/13/2026
Potential FDA approval of psychedelics impacts Japan
FDA approval of psychedelics like ibogaine could influence Japanese pharmacy practices.
9/10/2026
FDA outlines new psychedelic drug framework in NEJM
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
9/8/2026
Ibogaine and the bicameral mind book release highlights growing interest
Jonathan Dickinson's new book explores ibogaine's therapeutic potential amid rising U.S. policy focus.
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/20/2026
Doctor critical of abortion meds nominated for FDA leadership
Nominee previously advocated for tighter controls on abortion medications.
8/19/2026
Trump's FDA pick Overton may boost psychedelics, pain meds
Heidi Overton's nomination could advance psychedelic therapies but raises vaccine concerns.
8/19/2026
University of Miami submits ibogaine application to federal authorities
Trump announces transfer of ibogaine investigational drug application to accelerate research.
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.
7/24/2026
Trump administration fast-tracks ibogaine research
Psychoactive drug ibogaine gains attention for addiction treatment potential.
7/23/2026
Trump executive order boosts psychedelic therapy research
Order encourages psychedelic research, allocates $50M for state studies.